FORA Capital
STLN icon

FORA Capital’s Starling Oncology STLN Stock Holding History

FORA Capital’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$70.5K Buy
+11,155
New +$66.7K ﹤0.01% 609

Other funds holding STLN

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Wexford Capital
Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

FORA Capital's STLN Position: Q3 2026 in Review

FORA Capital opened a new position in Starling Oncology (STLN) in Q3 2026: 11,155 shares worth $70.5K. The stake represents ﹤0.01% of the portfolio and ranks #609 among its holdings.

91 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • FORA Capital held 11,155 shares of Starling Oncology worth $70.5K as of Q3 2026.
  • Starling Oncology was a new FORA Capital position in Q3 2026.
  • Starling Oncology made up ﹤0.01% of FORA Capital's portfolio in Q3 2026, its #609 holding.
  • 91 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on FORA Capital's 13F filing for Q3 2026, filed 13 Nov 2026.